September Webinar: Update on COVID-19 and Thrombosis Risk

Register here.

Public Health Webinar Series on Blood Disorders  

Bringing Science into Practice

The Division of Blood Disorders is proud to offer this webinar series, providing evidence-based information on new research, emerging issues of interest in blood disorders, as well as innovative approaches to collaboration.

Update on COVID-19 and Thrombosis Risk 

September 17, 2020 • 2:00–3:00pm ET 

David Garcia, MD

Associate Medical Director of Anti-Thrombotic Therapy at the University of Washington Medical Center

Professor of Medicine, Division of Hematology, UW School of Medicine

Kristen M. Sanfilippo, MD, MPHS

Assistant Professor of Medicine, Division of Hematology, Washington University School of Medicine in St. Louis

Staff Physician, Division of Hematology/Oncology, John Cochran Veterans Administration Medical Center St. Louis

Adam Cuker, MD, MS

Associate Professor of Medicine and of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania

Director, Penn Comprehensive Hemophilia and Thrombosis Program

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease (COVID-19), has now spread to more than 180 countries. As of August 2, 2020, more than 17 million confirmed cases of COVID-19 and more than 680,000 associated deaths have been reported worldwide.

Peer-reviewed reports from centers in several different parts of the world have raised the concern that the risk of venous thromboembolism (VTE) may be unusually high in patients with SARS-CoV-2 infection, even when standard pharmacologic prophylaxis is administered.

However, the published evidence varies with respect to the magnitude of risk increase, and there are still many unanswered questions, including:

• What are the mechanisms by which this virus may promote venous thrombosis more than other infectious diseases that cause critical illness?
• Should higher-intensity anticoagulant therapy be used in some patients or would thrombosis prevention strategies (e.g. anti-inflammatory or immunosuppressive agents) be more effective?
• Would the benefits of post-discharge VTE pharmacologic prophylaxis outweigh the risks after hospitalization for COVID-19?

Learning Objectives:

1. Summarize the evidence from peer-reviewed publications of COVID-19-associated VTE.
2. Describe proposed mechanisms by which COVID-19 may increase the risk for VTE.
3. Recount the latest guidelines for preventing VTE in patients who are hospitalized for COVID-19.

This webinar is free and open to public health professionals, clinicians, and researchers who desire more information about thrombosis and COVID-19. Advance registration is required, and the number of attendees is limited.

Please preregister here: https://bit.ly/30NiD0P

For more info please contact Cynthia Sayers: cay1@cdc.gov

National Center on Birth Defects and Developmental Disabilities, Division of Blood Disorders